Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon

Brain Waves

Monthly Archives

February 9, 2010

The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics

Email This Entry

Posted by Zack Lynch

120_Neurodiagnostics_Report_Cover_200.jpgWe've recently published "The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics," a report published by NeuroInsights. It is a fully updated second annual industry insider report detailing markets and emerging diagnostics in neurology and psychiatry. In addition to the massive unmet markets, long-term growth in neurodiagnostics is being driven by technology advances and equipment upgrades in neuroimaging; new biomarkers and imaging protocols for early diagnosis and disease monitoring; and increased use of imaging and informatics in drug and device development.

NeuroInsights has identified three primary markets in neurodiagnostics which are discussed in detail in this report: Neuroimaging: Medical equipment and reagents for research, diagnostics and patient monitoring, including MRI, CT, PET, SPECT, EEG and MEG. In vitro diagnostics: Genetic testing, biomarker assays and chemical profiling of human samples, including urine, blood, cerebral spinal fluid and tissue. Neuroinformatics: Multidimensional databases and software systems that store and analyze data from the genetic to the behavioral level.

Partial list of companies discussed in the report include: Abbot Diagnostics, Adlyfe, Advanced Brain Monitoring, Applied NeuroSolutions, Aspect Medical (Covidien), Astro-Med, Athena Diagnostics, Avacta, Avid Radiopharmaceuticals, Bayer, BioBehavioral Diagnostics, Brain Resource, BrainScope, Cambridge Cognition, CNS Response, CNS Vital, CogState, Compumedics, Cytox, Electrical Geodesics, Elminda, ExonHit, GE, GeneNews, g-Nostics, Hitachi, Johnson & Johnson, Kappametrics, Knopp Neurosciences, Michael J. Fox Foundation, Natus Medical, NeuroMetrix, Neuronetrix, Neuroptix, NeuroTrax, NeuroVigil, NeuroVista, Nymox, Odin, Optima Neuroscience, Optimal Medicine, Orasi Medical, Ortho-Clinical Diagnostics, Pfizer, Philips, PhysioSonics, Pritzker Neuropsychiatric Consortium, Psynova, Quest Diagnostics, Roche, Rules-Based, Medicine, Satoris, Siemens, SleepMed, The Genetics Company, TheraGenetics, Toshiba,Transcription Diagnostics, Vanda, Wyeth and more. To view the full list of 150 companies included in this extensive report, click here.

Comments (0) + TrackBacks (0) | Category: Neurodiagnostics

February 1, 2010

Neuropharma FDA Approvals Down in 2009

Email This Entry

Posted by Zack Lynch

200_Neurosurgery-Cover.jpgAs we report today in this month's edition of Neurotech Insights, five of the 26 new drugs and biologics approved by the FDA were neuropharmaceuticals: Vanda/Novartis’ Fanapt for schizophrenia, Lundbeck's Sabril for infantile spasms and add-on for refractory partial seizures, Cypress/Forest’s Savella for fibromyalgia, Merck's (Organon) Saphris for bipolar and schizophrenia, and Novartis’ branded version of betaseron for multiple sclerosis.. This compares to seven neuropharmaceutical approvals out of 24 in 2008 (Pristiq, Relistor, Entereg, Xenazine, Vimpat, Banzel and tapentadol) and only two of 17 in 2007.

Comments (0) + TrackBacks (0) | Category: Neuropharma